Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 21 Jul 2018
At a glance
- Drugs Doxorubicin (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 05 Jun 2018 Results (n=170) of a retrospective exploratory analysis assessing association between platelet count and outcome of patients, presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 07 Jun 2016 Results assessing efficacy and safety, presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
- 10 Feb 2013 New source identified and integrated (Robert H. Lurie Comprehensive Cancer Center, Northwestern University: CALGB80802).